| Literature DB >> 26492518 |
J A Traherne1,2, W Jiang2, A M Valdes3, J A Hollenbach4, J Jayaraman2, J A Lane5, C Johnson2, J Trowsdale1,2, J A Noble5.
Abstract
Classical human leukocyte antigens (HLA) genes confer the strongest, but not the only, genetic susceptibility to type 1 diabetes. Killer cell immunoglobulin-like receptors (KIR), on natural killer (NK) cells, bind ligands including class I HLA. We examined presence or absence, with copy number, of KIR loci in 1698 individuals, from 339 multiplex type 1 diabetes families, from the Human Biological Data Interchange, previously genotyped for HLA. Combining family data with KIR copy number information allowed assignment of haplotypes using identity by descent. This is the first disease study to use KIR copy number typing and unambiguously define haplotypes by gene transmission. KIR A1 haplotypes were positively associated with T1D in the subset of patients without the high T1D risk HLA genotype, DR3/DR4 (odds ratio=1.29, P=0.0096). The data point to a role for KIR in type 1 diabetes risk in late-onset patients. In the top quartile (age of onset>14), KIR A2 haplotype was overtransmitted (63.4%, odds ratio=1.73, P=0.024) and KIR B haplotypes were undertransmitted (41.1%, odds ratio=0.70, P=0.0052) to patients. The data suggest that inhibitory 'A' haplotypes are predisposing and stimulatory 'B' haplotypes confer protection in both DR3/DR4-negative and late-onset patient groups.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26492518 PMCID: PMC4746488 DOI: 10.1038/gene.2015.44
Source DB: PubMed Journal: Genes Immun ISSN: 1466-4879 Impact factor: 2.676
Figure 1Schematic representation of common KIR haplotypes, with the predisposing tA01 gene group boxed in red. The gene content of tA01 and tA02 are the same, except that tA01 carries the 22 bp frameshift deletion form of KIR2DS4 (2DS4v; 2DS4*003, *004, *006, *007, *008, *009,* 010, *012, *013), whereas tA02 encodes the full-length gene (2DS4f). Figure adapted from Jiang et al.[8]
TDT analysis of full, centromeric and telomeric KIR haplotypes for type 1 diabetes association with stratification by DR3/4 status
| P | ||||||
|---|---|---|---|---|---|---|
| A1 | 236 | 183 | 6.70 | 56.3% | 1.29 (1.06–1.56) | |
| A2 | 91 | 91 | 0.00 | 1.00 | 50.0% | 1.00 (0.75–1.34) |
| B | 283 | 314 | 1.61 | 0.20 | 47.4% | 0.90 (0.77–1.06) |
| Others | 37 | 59 | 5.04 | 38.5% | 0.63 (0.42–0.95) | |
| A1 | 128 | 121 | 0.20 | 0.66 | 51.4% | 1.06 (0.83–1.36) |
| A2 | 53 | 53 | 0.00 | 1.00 | 50.0% | 1.00 (0.68–1.46) |
| B | 185 | 198 | 0.44 | 0.51 | 48.3% | 0.93 (0.76–1.14) |
| Others | 31 | 25 | 0.64 | 0.42 | 55.4% | 1.24 (0.73–2.10) |
| cA01 | 421 | 381 | 2.00 | 0.16 | 52.5% | 1.10 (0.96–1.27) |
| cB01 | 109 | 117 | 0.28 | 0.59 | 48.2% | 0.93 (0.72–1.21) |
| cB02 | 80 | 90 | 0.59 | 0.44 | 47.1% | 0.89 (0.66–1.20) |
| Others | 37 | 59 | 5.04 | 38.5% | 0.63 (0.42–0.95) | |
| cA01 | 232 | 220 | 0.32 | 0.57 | 51.3% | 1.05 (0.88–1.27) |
| cB01 | 67 | 87 | 2.60 | 0.11 | 43.5% | 0.77 (0.56–1.06) |
| cB02 | 67 | 65 | 0.03 | 0.86 | 50.8% | 1.03 (0.73–1.45) |
| Others | 31 | 25 | 0.64 | 0.42 | 55.4% | 1.24 (0.73–2.10) |
| tA01 | 324 | 266 | 5.70 | 54.9% | 1.22 (1.04–1.43) | |
| tA02 | 142 | 149 | 0.17 | 0.68 | 48.8% | 0.95 (0.76–1.20) |
| tB01 | 144 | 173 | 2.65 | 0.10 | 45.4% | 0.83 (0.67–1.04) |
| Others | 37 | 59 | 5.04 | 38.5% | 0.63 (0.42–0.95) | |
| tA01 | 181 | 189 | 0.17 | 0.68 | 48.9% | 0.96 (0.78–1.17) |
| tA02 | 93 | 98 | 0.13 | 0.72 | 48.7% | 0.95 (0.71–1.26) |
| tB01 | 92 | 85 | 0.28 | 0.60 | 52.0% | 1.08 (0.81–1.45) |
| Others | 31 | 25 | 0.64 | 0.42 | 55.4% | 1.24 (0.73–2.10) |
Abbreviations: CI, confidence interval; OR, odds ratio.
A B Full=haplotypes containing both the centromeric and telomeric groups. A1=3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4Del-3DL2; A2=3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B=haplotypes with at least one activating KIR gene; cA01=3DL3-2DL3-2DP1-2DL1-3DP1; cB01=3DL3-2DS2-2DL2-3DP1; cB02=3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01=2DL4-3DL1-2DS4Del-3DL2; tA02=2DL4-3DL1-2DS4FL-3DL2; tB01: 2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; others: haplotypes with frequency <1.0%.
TDT tests were performed separately for each affected sibling in a family. Testing using an average of the two siblings for each family gave similar results; however, the P-values did not reach statistical significance.
Significant P-values (> 0.05) are indicated with bold type. P-values are uncorrected based on prior hypothesis for KIR-T1D association.
Trans, number of transmitted haplotypes; N-trans, number of untransmitted haplotypes.
TDT analysis of full, centromeric and telomeric KIR haplotypes for type 1 diabetes association with stratification by age of onset
| P | ||||||
|---|---|---|---|---|---|---|
| A1 | 265 | 228 | 2.78 | 0.10 | 53.8% | 1.16 (0.97–1.39) |
| A2 | 96 | 117 | 2.07 | 0.15 | 45.1% | 0.82 (0.63–1.07) |
| B | 362 | 361 | 0.00 | 0.97 | 50.1% | 1.00 (0.87–1.16) |
| Others | 45 | 62 | 2.70 | 0.10 | 42.1% | 0.73 (0.49–1.07) |
| A1 | 95 | 70 | 3.79 | 0.0516 | 57.6% | 1.36 (1.00–1.85) |
| A2 | 45 | 26 | 5.08 | 63.4% | 1.73 (1.07–2.80) | |
| B | 102 | 146 | 7.81 | 41.1% | 0.70 (0.54–0.90) | |
| Others | 20 | 20 | 0.00 | 1.00 | 50.0% | 1.00 (0.54–1.86) |
| cA01 | 472 | 453 | 0.39 | 0.53 | 51.0% | 1.04 (0.92–1.19) |
| cB01 | 139 | 147 | 0.22 | 0.64 | 48.6% | 0.95 (0.75–1.19) |
| cB02 | 112 | 106 | 0.17 | 0.68 | 51.4% | 1.06 (0.81–1.38) |
| Others | 45 | 62 | 2.70 | 0.10 | 42.1% | 0.73 (0.49–1.07) |
| cA01 | 173 | 140 | 3.48 | 0.0621 | 55.3% | 1.24 (0.99–1.54) |
| cB01 | 37 | 56 | 3.88 | 39.8% | 0.66 (0.44–1.00) | |
| cB02 | 32 | 46 | 2.51 | 0.11 | 41.0% | 0.70 (0.44–1.09) |
| Others | 20 | 20 | 1.00 | 1.00 | 50.0% | 1.00 (0.54–1.86) |
| tA01 | 375 | 333 | 2.49 | 0.11 | 53.0% | 1.13 (0.97–1.31) |
| tA02 | 166 | 191 | 1.75 | 0.19 | 46.5% | 0.87 (0.71–1.07) |
| tB01 | 182 | 182 | 0.00 | 1.00 | 50.0% | 1.00 (0.81–1.23) |
| Others | 45 | 62 | 2.70 | 0.10 | 42.1% | 0.73 (0.49–1.07) |
| tA01 | 123 | 112 | 0.51 | 0.47 | 52.3% | 1.10 (0.85–1.42) |
| tA02 | 66 | 55 | 1.00 | 0.32 | 54.5% | 1.20 (0.84–1.72) |
| tB01 | 53 | 75 | 3.78 | 0.0518 | 41.4% | 0.71 (0.50–1.00) |
| Others | 20 | 20 | 0.00 | 1.00 | 50.0% | 1.00 (0.54–1.86) |
A B Full=haplotypes containing both the centromeric and telomeric groups. A1=3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4Del-3DL2; A2=3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B=haplotypes with at least one activating KIR gene; cA01=3DL3-2DL3-2DP1-2DL1-3DP1; cB01=3DL3-2DS2-2DL2-3DP1; cB02=3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01=2DL4-3DL1-2DS4Del-3DL2; tA02=2DL4-3DL1-2DS4FL-3DL2; tB01: 2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; Others: haplotypes with frequency <1.0%.
TDT tests were performed separately for each affected sibling in a family. Testing using an average of the two siblings for each family gave similar results; however, the P-values did not reach statistical significance.
Significant P-values (>0.05) are indicated with bold type. P-values are uncorrected based on prior hypothesis for KIR-T1D association.
Trans, number of transmitted haplotypes; N-trans, number of untransmitted haplotypes.